Clinical Trial Update: Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis [NA]

View source ↗

Summary

A clinical trial is evaluating pulsatile high-dose furmonertinib for EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Guangzhou University of Traditional Chinese Medicine | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis | NA | Status: RECRUITING